Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 13/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 5/20 | 0.35 |
| ▸ | KDM5A | P29375 | 3/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 4/20 | 0.35 |
| ▸ | KDM4A | O75164 | 4/20 | 0.35 |
| ▸ | KDM3A | Q9Y4C1 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | KDM6B | O15054 | 2/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.35 |
| ▸ | KDM4B | O94953 | 2/20 | 0.34 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.33 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3215577 | 0.89 | ALDH1A1 (0.37) | S1PR5ROCK1JMJD6 | |
| SCHEMBL1850872 | 0.86 | KDM4C (0.49) | KDM4CS1PR5ROCK1KDM5BKDM5A | |
| SCHEMBL3206270 | 0.83 | KDM4C (0.40) | KDM4CS1PR5KDM5BKDM5AKDM2B | |
| SCHEMBL1851577 | 0.81 | CYP2A6 (0.41) | S1PR5 | |
| SCHEMBL3207183 | 0.79 | KDM4C (0.38) | KDM4CROCK1KDM5BKDM5AKDM2B | |
| SCHEMBL1850714 | 0.76 | KDM4E (0.49) | KDM4CS1PR5ROCK1KDM5BKDM5C | |
| SCHEMBL3206278 | 0.72 | ALDH1A1 (0.35) | JMJD6 | |
| SCHEMBL1850224 | 0.70 | KDM4C (0.48) | KDM4CS1PR5KDM5BKDM5AKDM2B | |
| SCHEMBL3207187 | 0.69 | JMJD6 (0.33) | JMJD6 | |
| SCHEMBL1846917 | 0.69 | GPR52 (0.57) | KDM4CROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | KDM4C 2640/4885S1PR5 696/4885ROCK1 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.